Dr. Wang on Results With Crenolanib Plus Chemotherapy in AML
In Partnership With:
Eunice Wang, MD, chief, Leukemia Service, professor of Oncology, Departments of Medicine and Immunology, Roswell Park Cancer Institute, discusses the results of the combination of crenolanib plus chemotherapy in a study of patients with acute myeloid leukemia.
Eunice Wang, MD, chief, Leukemia Service, professor of Oncology, Departments of Medicine and Immunology, Roswell Park Cancer Institute, discusses the results of the combination of crenolanib plus chemotherapy in a study of patients with acute myeloid leukemia (AML).
The novel FLT3 inhibitor crenolanib was evaluated in combination with standard chemotherapy for patients with AML up to 60 years old who are FLT3-mutant. The quality of the remissions observed in this population were very good, says Wang, as 15 out of 16 patients in remission were minimal residual disease (MRD)-negative. Of the evaluable patients, the overall survival was 79% after almost 18 months, and the rate of relapse was 16% after a median follow-up of about 15 months, Wang adds.
These numbers compare favorably to the data seen with the RATIFY trial, which lead to the approval of midostaurin (Rydapt) for the treatment of adult patients with newly diagnosed FLT3-positive AML in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation.
